These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25629811)

  • 1. Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza.
    Med Lett Drugs Ther; 2015 Feb; 57(1461):17-9. PubMed ID: 25629811
    [No Abstract]   [Full Text] [Related]  

  • 2. Peramivir clearance in continuous renal replacement therapy.
    Thomas B; Hollister AS; Muczynski KA
    Hemodial Int; 2010 Jul; 14(3):339-40. PubMed ID: 20491974
    [No Abstract]   [Full Text] [Related]  

  • 3. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.
    Boltz DA; Ilyushina NA; Arnold CS; Babu YS; Webster RG; Govorkova EA
    Antiviral Res; 2008 Nov; 80(2):150-7. PubMed ID: 18573280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peramivir: an intravenous neuraminidase inhibitor.
    McLaughlin MM; Skoglund EW; Ison MG
    Expert Opin Pharmacother; 2015; 16(12):1889-900. PubMed ID: 26153242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.
    Sato M; Ito M; Suzuki S; Sakuma H; Takeyama A; Oda S; Watanabe M; Hashimoto K; Miyazaki K; Kawasaki Y; Hosoya M
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1643-9. PubMed ID: 25547357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peramivir for the treatment of influenza.
    Shetty AK; Peek LA
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.
    Arya V; Carter WW; Robertson SM
    Clin Pharmacol Ther; 2010 Nov; 88(5):587-9. PubMed ID: 20959843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peramivir: A Review in Uncomplicated Influenza.
    Scott LJ
    Drugs; 2018 Sep; 78(13):1363-1370. PubMed ID: 30196350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors.
    Komeda T; Ishii S; Itoh Y; Sanekata M; Yoshikawa T; Shimada J
    J Infect Chemother; 2016 Oct; 22(10):677-84. PubMed ID: 27497712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease.
    Takamatsu K; Marumo S; Fukui M; Hata A
    J Microbiol Immunol Infect; 2017 Aug; 50(4):541-544. PubMed ID: 28720319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baloxavir marboxil (Xofluza) for treatment of influenza.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):193-196. PubMed ID: 30653474
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous peramivir for treatment of influenza in hospitalized patients.
    Ison MG; Fraiz J; Heller B; Jauregui L; Mills G; O'Riordan W; O'Neil B; Playford EG; Rolf JD; Sada-Diaz E; Elder J; Collis P; Hernandez JE; Sheridan WP
    Antivir Ther; 2014; 19(4):349-61. PubMed ID: 23985625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
    Bantia S; Upshaw R; Babu YS
    Antiviral Res; 2011 Sep; 91(3):288-91. PubMed ID: 21722670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
    Barroso L; Treanor J; Gubareva L; Hayden FG
    Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials.
    Whitley R; Laughlin A; Carson S; Mitha E; Tellier G; Stich M; Elder J; Alexander WJ; Dobo S; Collis P; Sheridan WP
    Antivir Ther; 2015; 20(7):709-19. PubMed ID: 25318121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
    Wang PC; Fang JM; Tsai KC; Wang SY; Huang WI; Tseng YC; Cheng YS; Cheng TJ; Wong CH
    J Med Chem; 2016 Jun; 59(11):5297-310. PubMed ID: 27167096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
    Mancuso CE; Gabay MP; Steinke LM; Vanosdol SJ
    Ann Pharmacother; 2010; 44(7-8):1240-9. PubMed ID: 20516360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation.
    Komeda T; Ishii S; Itoh Y; Ariyasu Y; Sanekata M; Yoshikawa T; Shimada J
    J Infect Chemother; 2015 Mar; 21(3):194-201. PubMed ID: 25523716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
    Saisho Y; Ishibashi T; Fukuyama H; Fukase H; Shimada J
    Antivir Ther; 2017; 22(4):313-323. PubMed ID: 27805571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis.
    Lee J; Park JH; Jwa H; Kim YH
    Yonsei Med J; 2017 Jul; 58(4):778-785. PubMed ID: 28540991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.